Non-Melanoma Skin Cancer following Hydrochlorothiazide Use

Project Title Non-Melanoma Skin Cancer following Hydrochlorothiazide Use
Date Posted
Thursday, September 12, 2019
Project ID
cder_mpl1r_wp079
Status
Complete
Deliverables
Sentinel Modular Program Report: Non-Melanoma Skin Cancer following Hydrochlorothiazide Use
Related Links
Non-Melanoma Skin Cancer following Hydrochlorothiazide Use: A Propensity Score Matched Analysis
Duration of Use Among New Users of Hydrochlorothiazide (HCTZ), Angiotensin-Converting Enzyme Inhibitors (ACEIs), and Angiotensin II Receptor Blockers (ARBs)
Description

The goal of this request was to investigate the occurrence of non-melanoma skin cancer (NMSC) diagnoses among incident users of thiazide diuretics or comparator drugs of interest and to observe follow-up time after incident drug dispensing in the Sentinel Distributed Database (SDD). Data from January 1, 2000 to October 31, 2017 from 17 Data Partners contributing to the SDD were included in this report.

Medical Product
bendroflumethiazide (BFMTZ)
chlorothiazide (CTZ)
hydrochlorothiazide (HCTZ)
Health Outcome
non-melanoma skin cancer
Population / Cohort
All individuals
Time Period
January 1, 2000 - October 31, 2017
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Sentinel Distributed Database (SDD)
FDA Center
CDER
Scroll to Top